Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Columnist Dagmar Munn has managed the shift to a rollator, scooter, and other assistive devices that help her live a better ...

MaaT033, an experimental oral therapy for improving gut microbiome health, was shown to be safe and well tolerated in ALS ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

When a friend drops off gourmet ingredients from out of town, columnist Kristin Neva's family gets to enjoy a new cooking experience at home.

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...

Columnist Kristin Neva recognizes the distinction between being thankful "in" a bad situation rather than "for" a bad situation.

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a ...